| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Glomerulonephritis | |||||
| Lupus Nephritis | |||||
| Systemic Lupus Erythematosus | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Lupus Erythematosus, Systemic | |||||
| Nephritis | |||||
| 3 | More general conditions related to this trial | ||||
| Autoimmune Diseases | |||||
| Connective Tissue Diseases | |||||
| Immune System Diseases | |||||
| Kidney Diseases | |||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| SQ Fludarabine | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Cyclophosphamide | |||||
| Fludarabine | |||||
| Fludarabine monophosphate | |||||
| 6 | More general drug interventions related to this trial | ||||
| Alkylating Agents | |||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Alkylating | |||||
| Antirheumatic Agents | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Myeloablative Agonists | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | |||||
|
